Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• New research, recent controversies question vitamin D benefits in CVD
• REWIND: Assessing the role of dulaglutide for primary prevention of CVD Bolanle Akinyele, MD; Sudipa Sarkar, MD, MSCI; Roger S. Blumenthal, MD
• At Issue: Lancet initiative sparks discussion on diversity in cardiology
• FDA advises clinicians to discuss risks of paclitaxel-coated devices with patients
• TAVR systems approved for low-risk patients
• Endovascular-first approach bests open surgery for amputation-free survival in CLI
• Former NFL players at great risk for AF
• Geographic region impacts high-intensity statin use after MI
• Guideline-based statin use, adherence higher with cardiologist care
• High-risk patients unable to take PCSK9 inhibitors have poor outcomes
• Hormone therapy affects heart fat in women during menopause
• MI probability, outcomes may be predicted with high-sensitivity troponin
• Smoking cessation for 30 years confers reduced PAD risk similar to never smokers
• Volanesorsen decreases triglycerides in familial chylomicronemia syndrome
• Community-based mobile intervention improves CV health in black adults
• Once-weekly exenatide reduces MACE risk in patients with type 2 diabetes, CVD
• Preventive cardiology: Setting the stage for integration of lipids, diabetes and the heart
• SGLT2 inhibitors may have great potential in reducing HF in diabetes
• Synthetic marijuana poses risk for cardiotoxicity Michael J. Scalese, PharmD, BCCP, BCPS, CACP; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
• APACE
• APPROACH
• BASEL IX
• CRIC
• LATERAL
• QDOT-FAST
• RIKADA
• RIPPAF